-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Either because of business restructuring, or because of the failure of R&D projects, or because product sales are not as expected.
.
.
there are frequent layoffs in pharmaceutical companies
.
Near the end of the year, in the pharmaceutical field, many pharmaceutical companies have accelerated their pace of personnel adjustment
.
Many pharmaceutical companies stated that internal adjustments have been made through splits, layoffs and other actions to achieve performance growth
.
It is understood that November is the month when pharmaceutical companies lay off more employees
.
On November 18, 2021, the Michigan-based drugmaker Esperion will lay off 40% of its workforce, or about 170 employees.
The company stated that the plan will reduce costs by at least $80 million each year in 2021 and 2022
.
On November 15, 2021, South San Francisco-based Rigel Pharmaceuticals announced that it is cutting its workforce by 16%
.
It is reported that the company plans to cut 31 positions before the end of this year, and collect 3.
3 million US dollars in severance pay and modify stock options in the fourth quarter
.
The company said that starting from 2022, the plan will save between 11 million and 15 million U.
S.
dollars per year
.
On November 11, 2021, Lundbeck plans to remove 300 positions and use some of the money saved to support the CGRP migraine drug Vyepti (eptinezumab)
.
It is reported that in order to continue to promote future growth, Lundbeck Pharmaceuticals is cutting expenditures elsewhere
.
Coupled with the fierce competition in the migraine market, the companies that have gone public are all large companies whose strength cannot be underestimated, and Lingbei Pharmaceuticals is under great pressure
.
According to the data, there are currently seven drugs that have been marketed for this target worldwide, including Lundbeck Pharmaceuticals, including Amgen, Novartis, Daiichi Sankyo, Eli Lilly, etc.
, and the indications are all for migraine
.
In addition, there has been news recently that Novo Nordisk intends to lay off 15-20% of its employees nationwide.
.
The targets of this batch of layoffs are mainly employees during the probation period and some employees whose contracts will expire soon.
The product line of this layoff is more concentrated on such special lines of basal insulin full-time, and the mixed line may involve less
.
In addition to November, many pharmaceutical companies announced layoffs in October
.
According to Fierce pharma on October 13, 2021, Ardelyx plans to lay off 65% of its employees because the FDA will not provide clear information to biopharmaceutical companies on the prospects of its chronic kidney disease drugs
.
The pharmaceutical company also publicly stated that a new round of layoffs will take effect on December 15
.
According to Fierce pharma on October 12, 2021, a former Novartis plant in California is shrinking operations
.
In a notice to the California authorities, Mylan (Mylan) stated that it plans to close a factory in San Carlos and to lay off 75 employees from January 7, 2022
.
The market conditions in the pharmaceutical market are volatile.
In order to "scrape down on food and clothing," former pharmaceutical leaders have joined the ranks of layoffs
.
Analysts said that on the whole, whether it is a local pharmaceutical company or a multinational pharmaceutical company, under the influence of the pharmaceutical environment, they will choose to adjust the corporate structure, and personnel changes have become an important one
.
Accompanied by these adjustments, it will further intensify the flow of talents and competition between enterprises
.
In addition, September was a difficult month for biopharmaceuticals, and many pharmaceutical companies announced layoffs.
.
For example, on September 27, 2021, ZIOPHARM Oncology announced that as part of the restructuring plan, it was reducing its staff by 50%, or about 60 positions; on September 15, 2021, Sanofi closed Principia’s San Francisco laboratory, and Dismissal of 36 employees; In mid-September 2021, Theravance Biopharma announced plans to reduce its workforce by 75%; in early September 2021, Amarin announced its Vascepa’s new marketing strategy in the United States.
The company has approximately 750 sales representatives and plans to This number was reduced to more than 50%, reaching 300 people
.
.
.
there are frequent layoffs in pharmaceutical companies
.
Near the end of the year, in the pharmaceutical field, many pharmaceutical companies have accelerated their pace of personnel adjustment
.
Many pharmaceutical companies stated that internal adjustments have been made through splits, layoffs and other actions to achieve performance growth
.
It is understood that November is the month when pharmaceutical companies lay off more employees
.
On November 18, 2021, the Michigan-based drugmaker Esperion will lay off 40% of its workforce, or about 170 employees.
The company stated that the plan will reduce costs by at least $80 million each year in 2021 and 2022
.
On November 15, 2021, South San Francisco-based Rigel Pharmaceuticals announced that it is cutting its workforce by 16%
.
It is reported that the company plans to cut 31 positions before the end of this year, and collect 3.
3 million US dollars in severance pay and modify stock options in the fourth quarter
.
The company said that starting from 2022, the plan will save between 11 million and 15 million U.
S.
dollars per year
.
On November 11, 2021, Lundbeck plans to remove 300 positions and use some of the money saved to support the CGRP migraine drug Vyepti (eptinezumab)
.
It is reported that in order to continue to promote future growth, Lundbeck Pharmaceuticals is cutting expenditures elsewhere
.
Coupled with the fierce competition in the migraine market, the companies that have gone public are all large companies whose strength cannot be underestimated, and Lingbei Pharmaceuticals is under great pressure
.
According to the data, there are currently seven drugs that have been marketed for this target worldwide, including Lundbeck Pharmaceuticals, including Amgen, Novartis, Daiichi Sankyo, Eli Lilly, etc.
, and the indications are all for migraine
.
In addition, there has been news recently that Novo Nordisk intends to lay off 15-20% of its employees nationwide.
.
The targets of this batch of layoffs are mainly employees during the probation period and some employees whose contracts will expire soon.
The product line of this layoff is more concentrated on such special lines of basal insulin full-time, and the mixed line may involve less
.
In addition to November, many pharmaceutical companies announced layoffs in October
.
According to Fierce pharma on October 13, 2021, Ardelyx plans to lay off 65% of its employees because the FDA will not provide clear information to biopharmaceutical companies on the prospects of its chronic kidney disease drugs
.
The pharmaceutical company also publicly stated that a new round of layoffs will take effect on December 15
.
According to Fierce pharma on October 12, 2021, a former Novartis plant in California is shrinking operations
.
In a notice to the California authorities, Mylan (Mylan) stated that it plans to close a factory in San Carlos and to lay off 75 employees from January 7, 2022
.
The market conditions in the pharmaceutical market are volatile.
In order to "scrape down on food and clothing," former pharmaceutical leaders have joined the ranks of layoffs
.
Analysts said that on the whole, whether it is a local pharmaceutical company or a multinational pharmaceutical company, under the influence of the pharmaceutical environment, they will choose to adjust the corporate structure, and personnel changes have become an important one
.
Accompanied by these adjustments, it will further intensify the flow of talents and competition between enterprises
.
In addition, September was a difficult month for biopharmaceuticals, and many pharmaceutical companies announced layoffs.
.
For example, on September 27, 2021, ZIOPHARM Oncology announced that as part of the restructuring plan, it was reducing its staff by 50%, or about 60 positions; on September 15, 2021, Sanofi closed Principia’s San Francisco laboratory, and Dismissal of 36 employees; In mid-September 2021, Theravance Biopharma announced plans to reduce its workforce by 75%; in early September 2021, Amarin announced its Vascepa’s new marketing strategy in the United States.
The company has approximately 750 sales representatives and plans to This number was reduced to more than 50%, reaching 300 people
.
